Kornimate/medical-research-clean huggingface dataset:
collagenase in the treatment of zone ii flexor tendon adhesions in the hand

Conditions: Adhesion of Flexor Tendon of Hand

Summary: the purpose of this study is to dissolve flexor tendon adhesions associated with failed tendon repair surgery.

in an open label study, collagenase injection therapy was investigated in 3 subjects for it's ability to lyse flexor tendon adhesions in zone ii of the hand. results indicate that two of three subjects had improved range of finger motion at the pip and dip joints. this may obviate the need for patients to have tenolysis hand surgery to correct the finger flexion contracture of the pip and dip joints. detailed controlled studies remain to be done.

Eligibility criteria:
inclusion criteria: * zone ii flexor tendon adhesion of at least one finger exclusion criteria: * any chronic, serious or uncontrolled medical condition * inability to conform to study visits (12-15 per year)

Keywords: flexor tendon adhesions zone ii of the hand
bright light therapy in seasonal affective disorder (sad)

Conditions: Seasonal Affective Disorder

Summary: bright light therapy (blt) is widely accepted as first-line treatment of seasonal affective disorder (sad). however, the mechanism of action of blt is still widely unknown. on the other hand, in mammals, light penetrates the skull bone and reaches the brain, and extra ocular transcranial phototransduction has physiological influences such as changed reproductive cycles and increased brain serotonin levels. therefore, the investigators run a randomized, placebo controlled, double blind, dose finding study on the putative effect of transcranial bright light in the treatment of sad.


Eligibility criteria:
inclusion criteria: • a patient has (according to the diagnostic and statistical manual of mental disorders, fourth edition, text revision \[dsm-iv-tr\]) a major depression, recurrent episode, seasonal pattern, "moderate" or "severe" (classification code 296.32 and 296.33) the 29-item structured interview guide for hamilton depression rating scale - seasonal affective disorder version (sigh-sad) score ≥ 20 * the 29-item structured interview guide for hamilton depression rating scale - seasonal affective disorder version (sigh-sad) score ≥ 20 * the 21-item hamilton depression rating scale score ≥ 10 * the 8-item atypical symptom score ≥ 5 * patient is over 18 years * patient can read and understand the subject information sheet * patient has signed the informed consent form * patient is not pregnant exclusion criteria: * patient has a lifetime psychotic disorder * patient has a dsm-iv axis i disorder other than some anxiety disorder evaluated by mini * patient has some dsm-iv-tr axis ii disorder, which is likely to interfere with the study treatment according to the investigator * patient has alcohol or some other substance use dependence or misuse * patients has some unstable somatic disorder * patient uses some psychotropic agencies * patient is, in the opinion of the investigator, unsuitable for any reason * patient is a member of the site personnel or their immediate families * patient has had bright light therapy via ear canals during the current episode
study of gemcitabine and abraxane for pancreas cancer

Conditions: Pancreatic Cancer

Summary: a phase ii trial of gemcitabine plus nab-paclitaxel in the second line setting

this is an open label phase ii study to evaluate the clinical activity of the combination of gemcitabine and nab-paclitaxel (abraxane) as second line treatment in patients with metastatic pancreatic cancer who have received non-gemcitabine-based chemotherapy in the first line setting. all patients will receive both drugs on days 1, 8, 15 every 28 days. the hypothesis is that this combination will have a 4-month progression free survival of 70% or higher.

Eligibility criteria:
inclusion criteria: * histologically confirmed metastatic adenocarcinoma of the pancreas * progression on first line non-gemcitabine based therapy for metastatic or relapsed disease * radiographically measurable or evaluable disease * age \>/= 18 years * ecog performance status 0-2 * adequate hepatic, bone marrow and renal function exclusion criteria: * prior gemcitabine-based chemotherapy in the first line setting * no active severe infection, or known chronic infection with hiv or hepatitis b virus * no cardiovascular disease problems including unstable angina, therapy for life-threatening ventricular arrhythmia, or myocardial infarction, stroke, or congestive heart failure within the last 6 months * no women who are pregnant or breastfeeding, and no women of childbearing potential without using dual forms of contraception * patients with known cns metastases * history of allergic reactions attributed to compounds of similar chemical or biologic composition to gemcitabine or nab-paclitaxel * anticipated patient survival under 2 months

Keywords: metastatic pancreatic cancer second line treatment gemcitabine nab-paclitaxel
a prospective, with one site, open-label not controled trial, for the observation of treatment with cidofovir 1%, 3 nights per week, during 4 weeks, of anal intraepithelial neoplasia, high level, in hiv+ patients

Conditions: HIV

Summary: cidofovir could be an effective drug for the treatment of anal intraepithelial neoplasia(ain).


Eligibility criteria:
* inclusion criteria: 1. patients who have given informed consent in writing of the study before making any specific selection procedure for the study. 2. adult patients (18 years) with documented hiv infection, with high-grade ain demonstrated by biopsy, and have not received any prior treatment for anal intraepithelial neoplasia in the last 12 weeks. 3. for women of childbearing potential, negative pregnancy test in urine screening visit. all women of childbearing age should continue effective contraception throughout the study treatment. * exclusion criteria: 1. patients who have received previous treatment of anal intraepithelial neoplasia (ain) in the last 12 weeks. 2. dermatoses in patients with anogenital area 3. patients with a history of pre-invasive neoplasia associated with human papilloma virus 4. patients with a history of previous neoplasm, of any origin and location, in the past 5 years. 5. patients with a history of hematologic abnormalities, kidney or liver 6. pregnant or breastfeeding women or women of childbearing age who do not wish to use adequate contraception at the discretion of the investigator. 7. any disease or condition of the patient which, in the opinion of the investigator, is not adequate patient participation in the study.
a study to evaluate the efficacy and safety of rosuvastatin in the treatment of the carotid atherosclerotic plaques

Conditions: Carotid Atherosclerosis

Summary: this is a 2-year, open-label, randomized study to evaluate the efficacy of rosuvastatin dosing adjustment by ldl-c level compared to that of 5mg maintenance dose in chinese patients with carotid atherosclerosis.

this will be a 2-year, randomized, open-label, prospective, parallel-group study. it only be held in china-japan friendship hospital. subjects with carotid atherosclerosis plaques who meet all inclusion and none of the exclusion criteria will be randomized in a 1:1 ratio to receive treatment of rosuvastatin (5 mg, 10mg, 20mg) dosing adjustment by ldl-c level or fixed dose 5 mg. the study will consist of two phases: the screening/baseline period（-1to week 0）and the follow-up period(0 to month 24). the follow-up period will comprise seven visits.

Eligibility criteria:
inclusion criteria: * subjects or legal guardian can understand and sign the written informed consent form; * ldl-c≥100mg/dl（2.6mmol/l）. * subjects with carotid atherosclerotic non-calcified plaques determined by color doppler ultrasound on carotid. ( plaque defined as limited intima media thickness≥1.5mm, according to the procedure of vascular ultrasound examination in 2009 chinese journal of ultrasonography ) * subjects had not been treated with statins, or one had been treated with antihyperlipidemics no more than 3 months within 12 months prior to screening. exclusion criteria: * subjects known to be allergic to the study medication, or any components . * uncontrolled hypothyroidism defined as the systolic blood pressure(sbp) \>180 mmhg or the diastolic blood pressure(dbp) \>100 mmhg. * concomitant with severe or frequent arrhythmia, such as atrial fibrillation, second or third degree atrioventricular block, sick sinus syndrome etc. * alanine aminotransaminase (alt) and /or aspartate aminotransferase (ast) \>1.5×uln (upper limit of normal). * subjects with myopathies，or the value of creatine kinase \>1.5×uln (upper limit of normal). * concomitant with chronic wasting diseases, whose life span was anticipated no longer than 2 years. * pregnant or nursing woman, and subjects with a pregnant plan during this study. * cognitive impairment, which may affect obtaining informed consent and participating in the study procedures. * unwilling to receive treatment or examinations outlined in protocol.

Keywords: rosuvastatin carotid atherosclerosis plaque crestor rosuvastatin calcium
the feiba novoseven comparative study

Conditions: Severe Hemophilia A With an Inhibitor

Summary: fenoc is a prospective, open-label, randomized, cross-over, multi-center study to investigate and compare the hemostatic effect and cost-efficacy of two different by-passing agents in the treatment of joint hemorrhages in subjects with severe hemophilia a and inhibitors. the study is designed as a clinical equivalency trial.

the incidence of inhibitors among people with severe hemophilia a has been documented as approximately 20-30% in several prospective studies. in such patients acute hemorrhages frequently occur and profoundly jeopardize health, with subsequent development of arthropathy. a common way of treating such bleeding episodes is to use bypassing agents. among these agents the prothrombin complex concentrate feiba has been widely used for many years. more recently, recombinant factor viia (novoseven) has been added to the therapeutic options. while both products have been found effective in treating hemorrhages, the number of injections given for a bleeding episode has ranged widely, and it is so far unknown whether one of the products might have a better effect in certain patients.

Eligibility criteria:
inclusion criteria: * congenital hemophilia a with an inhibitor and the need for by-passing agents in the case of joint bleeding. * an expected bleeding frequency of \>=3 joint bleeds per year. * informed consent given. * age of two or older. exclusion criteria: * other congenital and acquired bleeding disorders. * symptomatic liver disease. * life expectancy \<12 months.

Keywords: hemophilia a inhibitors
combined exercise training in patients with multiple sclerosis

Conditions: Multiple Sclerosis

Summary: it is stated that the affected cognitive functions in multiple sclerosis are learning, memory, attention, speed of information processing, visuospatial skills, and executive functions. the speed of information processing, visual learning and memory are the most frequently affected components in ms. for this reason, approaches to increase cognitive functions by activating neuroprotective mechanisms such as exercise in patients with ms are needed. the purpose of this study is to examine the effect of combined exercise training on cognitive functions in patients with ms.

the study was designed as a randomized, controlled, single-blind trial. this study will include patients with ms who 0-5.5 according to the extended disability status scale (edss) and between 18-65 years. the patient will be randomized into a combined training group and a control group. the patients in the control group will not apply an exercise training. the combined exercise training group will be given combined exercise training, consisting of pilates and aerobic exercise, three times during 8 weeks. both groups will be reevaluated 8 weeks after the initial assessment. statistical analyses will be performed using the spss software version 15 (spss inc. chicago, il, usa). the pre-training and post-training measurements of groups will be compared with the wilcoxon test. the significance level was set at p\< 0.05.

Eligibility criteria:
inclusion criteria: * ambulatory * stable phase of the disease without relapses in the last 3 month * edss between 2-5,5. exclusion criteria: * orthopedic, vision, hearing, or perception problems * any cardiovascular or pulmonary disease in which exercise is contraindicated

Keywords: cognitive function fatigue quality of life functional exercise capacity
effects of snakehead fish on iugr and lbw among second and third trimester women

Conditions: Pregnancy Related

Summary: this study uses a randomized controlled trial (rct) design, conducted on pregnant women in yogyakarta province, indonesia. this study aims to observe the effects of snakehead fish prepared-meal intervention on fetal growth measurement and birth outcomes. the subjects were randomly divided into two groups (random allocation), the treatment and control groups. subjects in the treatment group will be given supplementation of snakehead fish prepared-meal for lunch for 3 months daily, while subjects in the control group will not receive the intervention.

subjects in this study were divided into two groups; treatment group, who were given snakehead fish prepared-meal for lunch everyday, and control group who were not given any supplementation.all participants have already agreed to join this study by signing the informed consent at the beginning of the study. snakehead fish meal contained carbohydrate, protein (from snakehead fish), vegetables and fruit. the daily intake of snakehead fish meal were noted in the food record form independently by the subjects in the treatment group and would be reported periodically to the researcher. snakehead fish meal were given for about 3 months or until the mother deliver the baby. all participants in both group were examined once a month using 2d ultrasonography to measured fetal growth. after the baby was born, baby's birth weigth and birth length data were obtained through the mother and baby's health book.

Eligibility criteria:
inclusion criteria: 1. age ≤ 28 years 2. in the 2nd and 3rd trimesters 3. middle to lower economic status exclusion criteria: 1. anemia 2. preeclampsia 3. multiple gestational pregnancy 4. allergies to fish

Keywords: snakehead fish prepared-meal intrauterine growth restriction low birth weight randomized controlled trial
protective cooling measures to safeguard elderly people from dangerous summer heat

Conditions: Hyperthermia; Heat; Weather; Aging; Type2 Diabetes; Hypertension; Heat Stress

Summary: with the increasing incidence and severity of extreme heat events accompanying climate change, there is an urgent need for sustainable cooling strategies to protect heat-vulnerable older adults, who are at increased risk of adverse health events during heat stress. health agencies including the world health organization, the united states centers for disease control and prevention, and health canada currently recommend visiting a cooling centre or other air-conditioned location for 1-3 hours per day during extreme heat events to mitigate hyperthermia and strain on the cardiovascular system and therefore the risk adverse health events. however, our recent trial shows that while brief air-conditioning exposure is effective for reducing body temperature and cardiovascular burden in healthy older adults, the physiological impacts of cooling abate quickly following return to the heat. the purpose of this project is therefore to assess whether shorter but more frequent air-conditioning exposure provides more effective cooling than current recommendations (a single 1-3-hour cooling bout) in older adults with or without common chronic health conditions associated with increased vulnerability to extreme heat. this will be accomplished by evaluating physiological strain in older adults with and without diabetes and/or hypertension exposed for 8 hours to conditions reflective of extreme heat events in temperate, continental climates (35°c, 60% relative humidity). participants will complete 3 separate simulated heat event exposures: i) a control trial (no cooling throughout the 8-hour heat event); ii) a recommended cooling trial (3 hours of heat exposure followed by 2 hours cooling); and iii) a hybrid cooling trial (2 hours of heat exposure followed by 1 hour cooling, another 2 hours heat exposure followed by 1 hour cooling, and a final 2-hour heat exposure).


Eligibility criteria:
inclusion criteria: * adult aged 60-85 years * male or female * body mass index \< 35 kg/m2 * for participants with type 2 diabetes: at least one year lapsed since diagnosis and hemoglobin a1c 6.0-10.5%. * for participants with hypertension: at least one year lapsed since diagnosis or average resting blood pressure \>140 systolic or \>90 diastolic exclusion criteria: * currently smoking or quit \<5 years ago * moderate or serious medical conditions (other than type 2 diabetes or high blood pressure), particularly those known to influence physiological responses to heat exposure (e.g., diagnosed heart disease, neurological disorders) * heat adapted due to repeated exposure to hot environments (use sauna, recent travel to hot climates, other) * for participants with type 2 diabetes: "brittle" diabetes: unpredictable hypo- \& hyperglycemia. severe cardiovascular autonomic or peripheral neuropathy (guidelines.diabetes.ca/cpg)

Keywords: heat wave cooling center heat strain cardiovascular strain heat and health protection extreme heat events thermal comfort
an exploratory investigation of dietary supplementation and the effect on common symptoms of hormonal imbalance

Conditions: Hormone Disturbance

Summary: this is an open-label observational trial to study the effectiveness of a commercial dietary supplement and its effect on common symptoms of normal menstrual discomfort.

this is an open-label observational trial to study the effectiveness of a commercial dietary supplement and its effect on common symptoms of normal menstrual discomfort. it is hypothesized that the dietary supplement marketed as the daily will improve subjective wellbeing in trial participants. it is further hypothesized that the dietary supplement will improve plasma biomarkers that have been previously correlated with insulin resistance. a total of 45 participants will be recruited for the trial following screening, with the expectation that at least 35 will complete the trial. the trial will be fully remote, and all participants will undergo a menstrual cycle without intervention to establish a baseline, and then will be given the intervention (dietary supplement) for a second menstrual cycle.

Eligibility criteria:
inclusion criteria: * provision of signed and dated informed consent form * stated willingness to comply with all study procedures and availability for the duration of the study * female, aged 18-55 (roughly 75% 18-38 and 25% 45-55) * ability to take oral medication and be willing to adhere to the dietary supplement regimen (2 capsules per day) * willing to fast overnight (12+ hours) prior to the blood collection, and to perform an at-home fingerprick blood test * moderate self-reported discomfort related to perceived hormone imbalance. participants must answer b or c on at least 3 of the following questions: exclusion criteria: * current use of medication for high blood pressure or for blood thinning * diabetic, or on medication such as metformin or acarbose * pregnancy, breastfeeding, or attempting to become pregnant during study * known allergic reactions to components of the dietary supplement (sunflower oil, passionflower, berberine, or grape seed extract ) * has exercised 3+ times per week of 30 minutes or more per session on average over the past 6 month * on a ketogenic or vegan diet for more than the past 30 days * if hormonal birth control, cannot stop during the duration of the study.
evaluation of 3dcrt versus igrt and analysis of early response in head and neck cancer.

Conditions: HEAD AND NECK CANCER; CARCINOMA OROPHARYNX; CARCINOMA PYRIFORM SINUS; CARCINOMA LARYNX

Summary: this study aims to study the impact image guided radiotherapy with cone beam ct will have on the outcomes(toxicities and response) of head and neck cancer when compared to 3d conformal radiotherapy without cbct based setup error verification.also,the various dosimetric variations in adaptive rt will be studied.

aims and objectives 1. to assess the patient's radiation dose planning for gtv, ctv and ptv for primary and nodal regions and derive comparison between igrt and 3d-crt. 2. to assess the dosimetric variation in different phases of adaptive rt due to changes in tumor shape and volume during the course of entire treatment in igrt arm in head and neck cancer patients. 3. to evaluate the optimal setup correction methodology using planar (epid) and volumetric images (cbct) in hnscc between 3d-crt and igrt treatment delivery respectively. 4. to compare the early tumour response and acute and chronic radiation morbidities between igrt and 3d-crt.

Eligibility criteria:
inclusion criteria: * histopathologically proven cases of carcinoma oropharynx,larynx,hypopharynx, stages t1-4 n0-2a m0 * informed consent * kps score \> 70 exclusion criteria: * uncontrolled medical comorbidity * not ready for follow up * previous cancer directed therapy

Keywords: igrt 3dcrt epid cbct hnscc
a study to learn about the safety of prevenar 20 vaccine in infants aged between two to six months

Conditions: Pneumococcal Disease

Summary: the purpose of this study is to learn about the safety of 20-valent pneumococcal conjugate vaccine (prevenar 20) under actual clinical practice in japan. this study is seeking for infants aged between two months to six months who are vaccinated with prevenar 20 for the first time. infants aged between two months and six months are normally given four vaccinations. the first three vaccinations are called primary vaccinations and are given with an interval of one month between each vaccination. the fourth vaccination is called the booster and is given between 12 and 15 months of age. participants will take part in this study from the day of first vaccination to 28 days after fourth vaccination. the side effects observed in the participants will be recorded and looked into.


Eligibility criteria:
inclusion criteria: 1. infants aged 2 months, inclusive, to 7 months, exclusive 2. those without a history of pneumococcal vaccination including prevenar 20 3. those who are expected to receive 4 doses 4. those whose parent or legal guardian understands the details of the study and provides consent to provision of information collected in the study to third parties and use of the information for other purposes. exclusion criteria:there are no exclusion criteria for this study.